$TLX

The 10 most shorted ASX stocks plus the biggest risers and fallers – Week 32

A weekly ASX short-selling recap (data lagged 4 days) lists the 10 most shorted stocks and the biggest changes in short interest. Healius entered the top ten, replacing Treasury Wine. Lotus Resources saw a 57.5% one-day short-interest dip after a $60m raise at 22c. Web Travel Group’s short interest fell ahead of a guidance beat and up to $90m buyback; shares rose 17.1%.

Original reporting
Published Aug 3, 2026, 2:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 5:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TLX
Neutral
low confidence
Mentioned
$TLX · $CAR · $LOT
Relevance
4/10
AlphAI data visualization · based on marketindex.com.au
Decision brief

The 30-second read

$TLXNeutralLow
01

Why it matters

The actionable signal is positioning. The clearest tradable catalyst in the text is Webjet’s 1H26 guidance beat plus an on-market buyback, which coincided with a large same-day rally and declining short interest. For Polynovo, the article links rising shorts to a FY26 trading update that missed consensus and flagged weaker US sales and commercial momentum.

02

Market read

Traders can use the short-interest changes as a sentiment/positioning overlay, but the article itself is not a new fundamental event for most names. The Webjet and Polynovo sections provide the most concrete catalyst linkage to price action and shorting behavior.

03

What to watch

Short-interest reporting is delayed and not mandatory until three business days after trades, so the snapshot may lag the latest fundamental developments and price moves.

Relevance 4/10Novelty 3/10Timing: short-selling data is 4 days behind; useful for positioning into the next session

Background

This is a weekly recap of the most heavily shorted ASX stocks and the biggest week-on-week changes in short interest, using data that lags by four days.

Company-level read

Ticker impact

$TLXNeutralLow confidence
Context

Telix Pharmaceuticals is in the most shorted group, with short interest essentially unchanged week-on-week (-0.01%) but down month-on-month (-0.56%).

Expected impact

Potential for stabilization rather than fresh downside.

Evidence & confidence

The article provides short-interest deltas only; without new trial or guidance details, the signal is weak.

$CARNeutralLow confidence
Context

CAR Group is listed among the most shorted ASX stocks, with short interest down 0.12% week-on-week.

Expected impact

Mild upward drift possible if the trend continues.

Evidence & confidence

The article does not provide a new CAR-specific fundamental catalyst, only short-interest movement.

$LOTNeutralLow confidence
Context

Lotus Resources remains among the most shorted, with short interest 22.49% and week-on-week -0.31%, month-on-month -0.33%.

Expected impact

High volatility risk remains due to elevated short %, but direction is unclear from the small declines.

Evidence & confidence

The article notes a prior one-day dip tied to a $60m raise at 22 cents, but the newest disclosed changes are modest WoW/MoM.

Market effects

Signals shifting sentiment across ASX healthcare, travel, and industrials, but without sector-wide regulatory or macro triggers.

Primarily affects Australian small-to-mid caps where short interest is meaningful; limited spillover to broader ASX indices implied.

Low, as the catalyst set is company-specific short-interest and guidance/buyback details for ASX-listed names.

Counterpoint

Rising short interest can coincide with oversold conditions; if the market is already pricing bad news, shorts may be late and vulnerable to squeezes.

Key entities

  • Webjet (Web Travel Group)

    Guidance update on 29 July topped revenue margin and FY26 EBITDA expectations, with an on-market buyback up to $90m; stock rallied 17.1% on the day.

  • Polynovo

    FY26 trading update on 23 July showed sales up 21.1% to $102.1m but short of consensus, with second-half US slowdown commentary; short interest rebuilt to 9.58%.

  • Healius

    Joined the top ten most shorted, with short interest up 0.55% week-on-week and 0.52% month-on-month.

  • Lotus Resources

    Remains highly shorted at 22.49% short %, with the article referencing a prior $60m raise at 22 cents per share tied to a one-day dip.

Related articles

$TLXHighAI 8/10

Buy, hold, sell: Domino's Pizza, Telix Pharmaceuticals, Westfarmers shares

Telix Pharmaceuticals (TLX) shares surged 10% to $17.99 after FDA approval for its brain cancer imaging drug, Pixclara, with analysts seeing 37% upside. Domino's Pizza (DMP) shares rose 1% to $19.14 despite a 11.2% revenue drop and $134.2M loss, with brokers suggesting a hold. Wesfarmers (WES) shares fell 0.5% to $72.42 after a mixed FY26 report, with most analysts recommending a sell.

$TLXHighAI 9/10

New FDA-approved brain cancer scan from Telix Pharmaceuticals (TLX) helps doctors see a key difference

Telix Pharmaceuticals (TLX) received FDA approval for Pixclara, a PET imaging drug for brain cancer (glioma). It's the first FDA-approved FET-PET imaging drug, addressing a significant unmet need in the U.S. Pixclara helps differentiate recurrent glioma from treatment-related changes, improving diagnostic accuracy. Telix is a commercial-stage radiopharmaceutical company with a portfolio of precision diagnostics and therapeutics.

$TLXHighAI 9/10

Telix's Pixclara Wins FDA Approval For Glioma Imaging In Adults And Children

Telix Pharmaceuticals (TLX) announced FDA approval for Pixclara, a PET imaging drug for glioma. Pixclara is the first FDA-approved FET-PET imaging drug in the U.S. and is indicated for adults and pediatric patients. The approval may expand U.S. access to FET-PET imaging and support diagnosis and treatment planning. TLX stock closed at $11.29 on Friday and is up 8.95% in pre-market trading.

$TLXHighAI 9/10

FDA approves Telix’s first FET-PET imaging drug for glioma

The FDA approved Telix Pharmaceuticals' Pixclara, the first FDA-approved FET-PET imaging drug for glioma. It helps differentiate glioma progression from treatment-related changes. Telix aims to expand its precision medicine platform into brain cancer, with Pixclara targeting amino acid transporters in glioma tissue. The approval addresses a significant unmet need in brain cancer imaging.

$TLXHighAI 8/10

Lunch Wrap: Telix gets the FDA tick as oil price spoils ASX mood

The ASX 200 was flat at lunchtime on Monday. Telix Pharmaceuticals (TLX) shares rose 4% after the FDA approved its PET imaging drug for glioma brain cancer. Other movers: Cleanaway (CWY) +4%, FleetPartners (FPR) +10%, REA Group (REA) in focus after ACCC contract changes. Oil prices surged above $107 due to Middle East tensions and a likely Fed rate hike.